A
1.14
0.12 (11.27%)
| Penutupan Terdahulu | 1.02 |
| Jumlah Dagangan | 1,385,483 |
| Harga / Buku (P/B) | 16.34 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -2.24 |
| Nisbah Semasa (MRQ) | 10.68 |
| Aliran Tunai Operasi (OCF TTM) | -22.96 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.95 M |
| Pulangan Atas Aset (ROA TTM) | -91.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -280.78% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Annovis Bio, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Nilai 35% | -1.7 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | -1.7 |
| Masa 35% | 0.4 |
| AI Technical info | NA |
| Osilator Teknikal info | -1.0 |
| Purata Bergerak Teknikal info | 2.5 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Persekitaran | ×1.21 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -22.4% |
| Persetujuan Tonggak | ×1.06 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 1.1 |
| Skor Akhir | -0.58 |
|
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 14.69% |
| % Dimiliki oleh Institusi | 16.09% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |